| Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer (NCT02153450) | Case Comprehensive Cancer Center | 2015-05-08 |
| Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer (NCT02048943) | Roswell Park Cancer Institute | 2015-03-01 |
| Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer (NCT01927393) | City of Hope Medical Center | 2014-12-01 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery (NCT02166255) | Wake Forest University Health Sciences | 2014-12-01 |
| Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung (NCT01741597) | City of Hope Medical Center | 2014-07-01 |
| Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers (NCT01846520) | City of Hope Medical Center | 2013-10-01 |
| Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer (NCT01924260) | Edward Kim | 2013-08-09 |
| CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT01839981) | Wake Forest University Health Sciences | 2013-07-01 |
| CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (NCT01835041) | Wake Forest University Health Sciences | 2013-04-01 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy (NCT01806675) | Sanjiv Sam Gambhir | 2013-03-04 |
| Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (NCT01666730) | Case Comprehensive Cancer Center | 2013-02-21 |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors (NCT01525082) | Shaheen Shagufta | 2012-12-01 |
| Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (NCT01473940) | Northwestern University | 2012-06-11 |
| Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer (NCT01191684) | City of Hope Medical Center | 2011-10-01 |
| Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery (NCT01234935) | Translational Oncology Research International | 2011-01-13 |
| PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer (NCT01227018) | Vanderbilt-Ingram Cancer Center | 2010-12-01 |
| Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT01222689) | National Cancer Institute (NCI) | 2010-11-01 |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (NCT01233505) | National Cancer Institute (NCI) | 2010-10-01 |
| Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer (NCT01232829) | National Cancer Institute (NCI) | 2010-10-01 |
| Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride (NCT00981162) | Roswell Park Cancer Institute | 2009-08-01 |
| Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer (NCT00735917) | National Cancer Institute (NCI) | 2008-10-01 |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer (NCT00577889) | National Cancer Institute (NCI) | 2008-03-01 |
| Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery (NCT00482625) | National Cancer Institute (NCI) | 2007-06-01 |
| Dasatinib in Treating Patients With Metastatic Pancreatic Cancer (NCT00474812) | National Cancer Institute (NCI) | 2007-05-01 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (NCT00397384) | National Cancer Institute (NCI) | 2007-01-01 |
| Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine (NCT00397787) | National Cancer Institute (NCI) | 2006-11-01 |
| Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients (NCT00383760) | National Cancer Institute (NCI) | 2006-08-01 |
| Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer (NCT00331682) | National Cancer Institute (NCI) | 2006-03-01 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (NCT00101348) | National Cancer Institute (NCI) | 2005-01-01 |
| Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas (NCT00085371) | National Cancer Institute (NCI) | 2004-07-01 |
| Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer (NCT00091026) | National Cancer Institute (NCI) | 2004-07-01 |
| Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00088894) | National Cancer Institute (NCI) | 2004-06-01 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer (NCT00087191) | National Cancer Institute (NCI) | 2004-05-01 |
| CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00075647) | National Cancer Institute (NCI) | 2003-12-01 |
| Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer (NCT00063947) | National Cancer Institute (NCI) | 2003-05-01 |
| Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer (NCT00047307) | National Cancer Institute (NCI) | 2002-08-01 |
| UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer (NCT00039403) | National Cancer Institute (NCI) | 2002-04-01 |
| Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer (NCT00031694) | National Cancer Institute (NCI) | 2002-03-01 |
| Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer (NCT00028834) | National Cancer Institute (NCI) | 2002-02-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498) | National Cancer Institute (NCI) | 2001-12-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer (NCT00019006) | National Cancer Institute (NCI) | 1995-03-01 |
| Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer (NCT00253526) | National Cancer Institute (NCI) | |